TABLE 1.
Patient characteristics.
| All patients (n = 25) | LGE + (n = 13) | LGE − (n = 12) | P value LGE + vs. LGE− | |
| Age, years | 62 (15) | 62 (13) | 61 (17) | 0.7 |
| Sex, female | 11 (44%) | 3 (23%) | 8 (67%) | 0.03 |
| Time to CMR (days) | 4.4 ± 2.4 | 3.8 ± 1.4 | 5.0 ± 3.1 | 0.29 |
| Cardiovascular risk factors | ||||
| Hypertension | 18 (72%) | 9 (69%) | 9 (75%) | 0.7 |
| History of smoking | 6 (24%) | 3 (23%) | 3 (25%) | 0.9 |
| Hyperlipidemia | 10 (40%) | 4 (31%) | 6 (50%) | 0.6 |
| Diabetes | 4 (16%) | 1 (8%) | 3 (25%) | 0.2 |
| Family history | 2 (8%) | 1 (8%) | 1 (8%) | 0.9 |
| Ischemic lesion | ||||
| Anterior circulation (ACA + MCA) | 19 (76%) | 12 (92%) | 7 (58%) | 0.9 |
| Insular region right side | 9 (36%) | 5 (39%) | 4 (33%) | 0.9 |
| Posterior circulation | 6 (24%) | 1 (8%) | 5 (42%) | 0.047 |
| Stroke severity, NIHSS score | 2 (7) | 3 (8) | 1 (5) | 0.4 |
| Stroke etiology | ||||
| TOAST 1 | 2 (8%) | 1 (8%) | 1 (8%) | 0.9 |
| TOAST 2 | 7 (28%) | 5 (39%) | 2 (17%) | 0.2 |
| TOAST 3 | 1 (4%) | 0 (0%) | 1 (8%) | 0.3 |
| TOAST 4 | 1 (4%) | 0 (0%) | 1 (8%) | 0.3 |
| TOAST 5 | 14 (56%) | 7 (54%) | 7 (58%) | 0.8 |
| Biomarkers | ||||
| Baseline hsTn, ng/l | 215 (963) | 414 (1808) | 115 (508) | 0.04 |
| Maximum hsTn, ng/l | 882 (1468) | 1280 (1796) | 235 (1089) | 0.02 |
| Time of max hsTn (hrs) | 6 (24) | 24 (22.5) | 3 (24) | 0.4 |
| Maximum CK, mg/dl | 127 (96) | 155 (233) | 98 (93) | 0.05 |
| NT-proBNP, ng/l | 1800 (4597) | 2029 (4936) | 1478 (6595) | 0.7 |
| CRP, mg/dl | 0.9 (1.4) | 0.8 (1.4) | 1.0 (1.3) | 0.6 |
| ECG | ||||
| ST-depression | 7 (28%) | 4 (31%) | 3 (25%) | 0.7 |
| Hemodynamics | ||||
| Heart rate | 79 (15) | 78 (15) | 80 (32) | 0.5 |
| Systolic BP | 156 (38) | 159 (41) | 154 (54) | 0.7 |
| Diastolic BP | 85 (23) | 90 (23) | 84 (24) | 0.5 |
| Renal function | ||||
| GFR (ml/min/1.73 m2) | 89 ± 35 | 100 ± 41 | 77 ± 23 | 0.1 |
| Medication at time of CMR | ||||
| Aspirin | 17 (68%) | 8 (62%) | 9 (75%) | 0.2 |
| P2Y12-inhibitor | 3 (12%) | 1 (8%) | 2 (17%) | 0.5 |
| DOAC | 5 (20%) | 4 (31%) | 1 (8%) | 0.5 |
| Statins | 21 (76%) | 12 (92%) | 9 (75%) | 0.3 |
| Beta-blockers | 14 (56%) | 7 (54%) | 7 (58%) | 0.8 |
| ACE inhibitors | 6 (24%) | 2 (12%) | 4 (33%) | 0.3 |
| CCBs | 4 (16%) | 1 (8%) | 3 (25%) | 0.3 |
| ARBs | 6 (24%) | 4 (31%) | 2 (17%) | 0.5 |
| Diuretics | 6 (24%) | 2 (15%) | 4 (33%) | 0.3 |
| Oral antidiabetics | 3 (12%) | 1 (8%) | 2 (17%) | 0.5 |
Values are given as frequency n (percentage%), or median (interquartile range). LGE, late gadolinium enhancement; CMR, cardiac magnetic resonance; ACA, anterior cerebral artery, MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; hs-cTnI, high sensitivity cardiac troponin I; CK, creatine kinase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; CRP, C-reactive protein; GFR, glomerular filtration rate; ECG, electrocardiogram; BP, blood pressure; GFR, glomerular filtration rate; DOAC, direct oral anticoagulant; ACE, angiotensin converting enzyme; CCBs, calcium channel blockers; ARBs, angiotensin receptor blockers. The statistically significant p ≤ 0.05 is represented by bold values.